Despite the groundbreaking success of tyrosine kinase inhibitor therapy, the management of chronic myeloid leukemia patients is often impaired by resistance due to specific point mutations in the BCR::ABL1 oncogene. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.